Stocks Health care INCY
NASDAQ · Health careIncyte Corp (INCY)
Incyte Corp brought in $6B of revenue over the twelve months to September 30, 2026, up 24.9% from a year earlier. Net income was $403.4M, a net margin of 6.7%. At September 30, 2026 it held $3.3B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Incyte Corp
- Net worth
- Incyte Corp has a market value (market cap) of $24.3B at the latest share price, and shareholders' equity of $5.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $5.1B (+21.2% year on year), with net income of $1.3B. Over the 12 months to September 30, 2026: revenue $6B, net income $403.4M.
- Cash flow
- In fiscal 2025 operations brought in $1.4B of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Incyte Corp's next report is expected around February 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Incyte Corp does
Incyte Corp is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker INCY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5.1B | $1.3B | $6.41 | n/a |
| 2024 | $4.2B | $32.6M | $0.15 | n/a |
| 2023 | $3.7B | $597.6M | $2.65 | n/a |
| 2022 | $3.4B | $340.7M | $1.52 | $892.1M |
| 2021 | $3B | $948.6M | $4.27 | $568.5M |
| 2020 | $2.7B | -$295.7M | -$1.36 | -$312M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where INCY ranks in Health care
Latest SEC filings
What Incyte Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 14% to $1.6B versus the same quarter last year; diluted EPS -$3.86 versus $2.11.
- October 29, 2026
- August 31, 2026Other event 8-K
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 38% to $1.7B versus the same quarter last year; diluted EPS $2.81 versus $2.04.
- July 28, 2026
- July 6, 2026Other event 8-K
- June 22, 2026Other event 8-K
- June 9, 2026
- June 8, 2026Other event 8-K
- May 27, 2026Additional proxy material DEFA14A
Insider trades
What the people running Incyte Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.5M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Tray ThomasPrincipal Accounting Officer | Soldpre-planned (10b5-1) | 610 | $72.6K |
| October 15, 2026 | Cagnoni Pablo JPresident, Global Head of R&D | Exercised options | 839 | $60.3K |
| October 15, 2026 | Cagnoni Pablo JPresident, Global Head of R&D | Exercised options | 423 | $26.1K |
| October 15, 2026 | Cagnoni Pablo JPresident, Global Head of R&D | Exercised options | 455 | $27.8K |
| October 15, 2026 | Cagnoni Pablo JPresident, Global Head of R&D | Exercised options | 925 | $59.4K |
| October 15, 2026 | Cagnoni Pablo JPresident, Global Head of R&D | Soldpre-planned (10b5-1) | 2,642 | $297.8K |
| October 1, 2026 | Heeson LeeEVP, Head of Incyte Intl | Shares withheld for tax | 463 | $54.2K |
| September 30, 2026 | Harrigan EdmundDirector | Received as pay | 206 | $25K |
Who owns INCY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Felix J. Baker13D, may seek influence with 6 related filers | 15.6% | May 11, 2026 |
| Incyte Corp13G, passive | 9.9% | November 7, 2025 |
| Vanguard Capital Management13G, passive | 6.32% | April 30, 2026 |
| Dodge & Cox13G, passive | 6.2% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 858 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Baker Bros. Advisors LP | 30,762,330 | +17,918 |
| BlackRock, Inc. | 18,032,718 | -945,480 |
| Dodge & Cox | 11,957,326 | -295,030 |
| Vanguard Capital Management LLC | 11,024,289 | +94,223 |
| State Street Corp | 9,722,336 | +80,952 |
| Vanguard Portfolio Management LLC | 7,791,091 | +31,908 |
| Aqr Capital Management LLC | 5,320,901 | -487,029 |
| Geode Capital Management, LLC | 4,750,735 | +47,551 |
| Invesco Ltd. | 4,080,461 | +209,697 |
| Wellington Management Group Llp | 3,575,521 | +309,385 |
| Renaissance Technologies LLC | 3,512,132 | -139,400 |
| Morgan Stanley | 2,948,364 | +98,036 |
| Arrowstreet Capital, Limited Partnership | 2,744,958 | -85,841 |
| Robeco Institutional Asset Management B.V. | 2,441,735 | -72,648 |
| Goldman Sachs Group Inc | 2,305,782 | -45,439 |
| Dimensional Fund Advisors LP | 2,280,803 | +305,259 |
| Two Sigma Investments, LP | 2,003,559 | +1,587,645 |
| Northern Trust Corp | 1,761,966 | -87,760 |
| Charles Schwab Investment Management Inc | 1,692,439 | -36,663 |
| Legal & General Group Plc | 1,605,980 | +62,792 |
Insiders
22 insiders reported holding 29,390,021 shares in total, about $3.52B at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector, 10% owner | 28,206,08228,206,082 held indirectly |
| Hoppenot HerveDirector | 326,803 |
| Cagnoni Pablo JPresident, Global Head of R&D | 183,200 |
| Meury WilliamChief Executive Officer, Director | 183,129 |
| Issa Mohamed KhairieEVP, Head of U.S. Commercial | 71,797 |
| Mayes Patrick AEVP & Chief Scientific Officer | 61,441 |
| Heeson LeeEVP, Head of Incyte Intl | 37,578 |
| Morrissey Michael JamesEVP, Head of Tech. Operations | 34,065 |
| Stein Steven HCMO & Head of Late-Stage Dev. | 30,916 |
| Denton Sheila A.EVP & General Counsel | 26,569 |
Questions about INCY
What does Incyte Corp do?
Incyte Corp is a company in the Health care sector, listed on NASDAQ as INCY. Its shares trade on NASDAQ under the ticker INCY.
What is Incyte Corp's net worth?
Incyte Corp has a market value (market cap) of $24.3B at the latest share price, and shareholders' equity of $5.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Incyte Corp profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $403.4M on revenue of $6B, a net margin of 6.7%.
How much revenue does Incyte Corp make?
Over the twelve months to September 30, 2026 Incyte Corp reported revenue of $6B. That is 24.9% more than a year earlier.
When did Incyte Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 6, 2026.
When is Incyte Corp's next earnings report?
Incyte Corp's next report is expected around February 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare INCY with
Follow INCY
Get an email when Incyte Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Incyte Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.